Key facts
- This page summarizes Vida Ventures, LLC's Form 4 filing for Kyverna Therapeutics, Inc. (KYTX).
- 6 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 14 Feb 2024, 19:04.
Vida Ventures, LLC - 12 Feb 2024 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- KYTX
- Reported as of
- 12 Feb 2024
- Net transaction value
- +$5,568,992
- SEC form
- 4
- Accepted by SEC
- 14 Feb 2024, 19:04:56 UTC
- Prior SEC filing
- 07 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- Vida Ventures, LLC By: /s/ Fred E. Cohen, its Senior Managing Director
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Vida Ventures, LLC filed Form 4 for Kyverna Therapeutics, Inc. (KYTX) on 14 Feb 2024.
Change
- Previous filing in this sequence was filed on 07 Feb 2024.
- Current net transaction value: +$5,568,992.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
KYTX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +4,523,924
- Change %
- Price
- Shares after
- 4,523,924
- Date
- 12 Feb 2024
- Ownership
- By Vida Ventures, LLC
- Footnotes
- F1, F2
KYTX
transaction
Common Stock
Purchase
- Transaction value
- $5,556,166
- Shares
- +252,553
- Change %
- Price
- $22.00*
- Shares after
- 252,553
- Date
- 12 Feb 2024
- Ownership
- By Vida Ventures III, L.P.
- Footnotes
- F3
KYTX
transaction
Common Stock
Purchase
- Transaction value
- $12,826
- Shares
- +583
- Change %
- Price
- $22.00*
- Shares after
- 583
- Date
- 12 Feb 2024
- Ownership
- By Vida Ventures III-A, L.P.
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KYTX
transaction
Derivative
Series A-1 Redeemable Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -4,401,771
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 12 Feb 2024
- Ownership
- By Vida Ventures, LLC
- Underlying class
- Common Stock
- Underlying amount
- 967,188
- Exercise price
- Footnotes
- F2, F5
KYTX
transaction
Derivative
Series A-2 Redeemable Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -8,830,901
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 12 Feb 2024
- Ownership
- By Vida Ventures, LLC
- Underlying class
- Common Stock
- Underlying amount
- 1,940,388
- Exercise price
- Footnotes
- F2, F5
KYTX
transaction
Derivative
Series B Redeemable Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- $0
- Shares
- -7,356,162
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 12 Feb 2024
- Ownership
- By Vida Ventures, LLC
- Underlying class
- Common Stock
- Underlying amount
- 1,616,348
- Exercise price
- Footnotes
- F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration.
Footnote F2
The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any.
Footnote F3
The shares of the Issuer's Common Stock are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
Footnote F4
The shares of the Issuer's Common Stock are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
Footnote F5
The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering.